Securing 2M
Summary
First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulationBOSTON, March 24, 2025 NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimers disease and brain cancers, and a subsidiary of Beyond Air (NASDAQ: XAIR), has secured an initial $2 million in equity financing from private investors as part of a larger funding round. Our NO-regulating therapy has the potential to address the underlying biological mechanisms of ASD, and we are committed to advancing a science-driven approach that could make a meaningful difference for children and families affected by autism.Autism is a complex condition with limited treatment options, added Prof. Haitham Amal, BScPharm, Ph.D., Chief Scientific Officer of NeuroNOS. The loss of dendritic spines, particularly in brain regions associated with social behavior and cognitive development, is believed to be a key driver of the social and developmental impairments seen in children with autism.By targeting and regulating NO levels, NeuroNOSs drug aims to restore normal brain signaling, prevent synaptic dysfunction, and ultimately improve both behavioral and cognitive function in children with ASD.To ensure the efficient production of its innovative drug, NeuroNOS is working with a U.S. based contract manufacturer. It is designed for subcutaneous injection or oral administration and aims to regulate nitric oxide (NO) levels in the brain, a mechanism that has shown significant promise in preclinical studies. Beyond Air is also advancing additional LungFit systems in clinical trials for severe lung infections, including viral community-acquired pneumonia (such as COVID-19) and nontuberculous mycobacteria (NTM).